TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025

Rhea-AI Summary

TNF Pharmaceuticals (Nasdaq: TNFA) has announced an upcoming investor conference call and webcast scheduled for March 6, 2025, at 4:30 pm ET. The event will feature Dr. Mitchell Glass, President and Chief Medical Officer, who will provide clinical updates on their lead drug candidate isomyosamine.

The company is currently conducting two significant clinical studies:

• A Phase 2b trial evaluating isomyosamine for treating chronic inflammation and muscle loss in hip/femur fracture repair patients
• New studies examining isomyosamine's potential in preserving lean muscle mass during and after GLP-1 weight loss treatments

Isomyosamine is a novel oral TNF-alpha inhibitor targeting immunometabolic dysregulation. Investors can participate via phone (877-407-0832) or webcast, with a 30-day replay available. Questions can be submitted in advance to rschatz@tnfpharma.com.

Concurrent clinical studies underway evaluating novel TNF-alpha inhibitor for treating muscle loss associated with hip/femur fracture repair, GLP-1 weight loss

Investors invited to submit questions prior to the event

BALTIMORE--(BUSINESS WIRE)-- TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it will host an investor conference call and webcast on Thursday, March 6, 2025, at 4:30 pm ET. Mitchell Glass, M.D., President and Chief Medical Officer of TNF, will provide a clinical scientific update on the Company’s lead candidate isomyosamine, a novel oral TNF-alpha (TNF-α) inhibitor drug shown to positively impact conditions related to immunometabolic dysregulation.

A Phase 2b clinical trial is currently underway to evaluate isomyosamine as a treatment for chronic inflammation associated with muscle loss (frailty or sarcopenia) in patients who have undergone hip or femur fracture repair surgery. Concurrently, TNF recently launched the first in a series of studies to evaluate the impact of isomyosamine for preserving lean muscle mass during and after GLP-1 obesity treatments for weight loss.

Conference Call and Webcast Access:

• Date and Time: Thursday, March 6, 2025, at 4:30pm ET
• Participant Dial-In: 877-407-0832 / +1 201-689-8433
• Live Webcast: Join here.
• Q&A Submit questions to rschatz@tnfpharma.com prior to the event
• 30-day phone replay: 877-660-6853 / 201-612-7415; Access ID: 13752199
• 30-day webcast replay: Same link above.

About Isomyosamine

Isomyosamine is a novel plant alkaloid small molecule shown to regulate the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines including TNF-alpha (TNF-α), an immune cell signaling protein and inflammatory cytokine responsible for inducing and maintaining the inflammatory process. TNF-α is located upstream of a cascade of molecular signals that induces inflammation and helps activate the process of aging. Many in vivo and in vitro studies have shown that TNF-α plays a causative role in the pathogenesis of various age-related diseases.

About TNF Pharmaceuticals, Inc.

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit www.tnfpharma.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “plan,” “will,” “would’’ and other similar expressions are intended to identify these forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the Company’s ability to launch, the success and timing of, the Company’s planned trial of isomyosamine (MYMD-1®) as a treatment for GLP-1-induced sarcopenia and frailty. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the Company’s ability to maintain compliance with the Nasdaq Stock Market’s listing standards; the timing of, and the Company’s ability to, obtain and maintain regulatory approvals for clinical trials of the Company’s pharmaceutical candidates; the timing and results of the Company’s planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company’s ability to retain and attract senior management and other key employees; the Company’s ability to quickly and effectively respond to new technological developments; and the Company’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company’s proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed by the Company on April 1, 2024, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250305398073/en/

Investor Contact:

Robert Schatz

(646) 421-9523

rschatz@tnfpharma.com

www.tnfpharma.com

Source: TNF Pharmaceuticals, Inc.

FAQ

What are the two main clinical trials TNFA is currently conducting with isomyosamine?

TNFA is conducting a Phase 2b trial for muscle loss in hip/femur fracture patients and studies on preserving muscle mass during GLP-1 weight loss treatments.

When is TNF Pharmaceuticals (TNFA) hosting their clinical update investor call?

TNF Pharmaceuticals is hosting their investor call and webcast on Thursday, March 6, 2025, at 4:30 pm ET.

How can investors participate in TNFA's March 2025 clinical update call?

Investors can dial in (877-407-0832), join via webcast, or submit questions in advance to rschatz@tnfpharma.com. A 30-day replay will be available.

What is the mechanism of action for TNFA's lead drug candidate isomyosamine?

Isomyosamine is a novel oral TNF-alpha inhibitor that targets conditions related to immunometabolic dysregulation.

How is TNFA connecting their research to the GLP-1 weight loss drug market?

TNFA is studying how isomyosamine can help preserve lean muscle mass during and after GLP-1 obesity treatments for weight loss.